Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2
Purpose To evaluate efficacy and safety of quarterly (and then monthly) ranibizumab during the 2-year P hase IIIb, multicenter, randomized, double-masked, sham i njection–controlled study of the e fficacy and…